201020102011 515 2010 05

BMJ 2009;339:b351370-7935-6970-7935-69

1.00.90.80.70 2 4 6 8 10 12 14 16 18 20 22n=6810n=686P=0.0001BMJ 1998;317:167-71.68647-55681022-232

36%243210(%)++1.93.0P=0.0005Lancet 2003;361:1149-58.P=0.0005ASCOT-LLA

27%36%020406080100Lancet 2003;361:1149-58.64%73%

10CHD35-791531525210CHDP 0.001Curr Med Res Opin 2011; 27:82133

BMJ 2003;326:14192380%

%95%CI6151-71179-2534639-536355-701611-202415-3375mg/d3223-40167-258884-918071-87

J Hum Hypertens. 2008;22(2):154-7.

Am J Hypertens.2010;23:229-236

MPASNSRASPDNOMPASNSRAS-PDNO

/ /TIA

Stary HC et al. Circulation. 1995; 92: 135574Fuster V et al. Vasc Med. 1998; 3: 2319.

GP IIb/IIIaGP IIb/IIIa5-PAFADPTXA2GP IIb/IIIa ADPADPAMP

,

N Engl J Med 2005, 352:1295-1304N=39876,ASA100mg qod vs. placebo,10yrsSBP 140 mmHgDBP 90 mmHg24%27%27%30%

Journal of Hypertension 2002, 20:23012307P=0.002P=0.003P=0.04P=0.03HOT> 1.3 mg/dl45%86%45%39%

603040501020 06045-59

JNC7National Heart, Lung, and Blood Institute (US); 2004 Aug. Report No.: 04-5230

1763

34%65432100654321789723535657HR 0.66,95%CL 0.56-0.77P

0%-10%-20%-30%-40%-35%-21%-25%-22% 0-2052031050253TPTBDATUK-TIALancet.2011 Jan 1;377(9759):31-41

HR95%CL0.650.53-0.780.790.69-0.910.750.67-0.840.780.70-0.87P

5-7.47.52520151050Lancet.Published Online December 7, 2010 HR 0.79, 95%CL 0.70-0.90, p=0.0003 HR 0.69, 95%CL 0.54-0.88, p=0.00321%31%

DNA

()Ann N Y Acad Sci. 2001 Dec;947:271-92Common approaches to therapy in atherosclerosis and cancer

Reduce oxidative stress by eliminating cigarette smoking, reducing dietary fat intake, and administering antioxidant therapeutics Use anti-inflammatory agents to reduce chemokine, cytokine, and growth factor signaling Employ anti-proliferative drugs targeting growth factor receptors to reduce cell proliferation (i.e., postangioplasty restenosis in coronary and carotid atherosclerosis) Reduce excess matrix digestion caused by metalloprotease hyperactivity Reduce NFB signaling with proteasome inhibitors Use antiangiogenesis strategies to delay plaque expansion in therosclerosis and cancer invasion and metastasis Use radiation treatment (not proven to date) to prevent restenosis after angioplasty and stent placement

NFDNA~~~~

Lancet 2009; 373: 1301-9.COX-2NFDNA

Professor Peter Rothwell, John Radcliffe Hospital, Oxford, and University of Oxford, UK, noted that previous guidelines have rightly cautioned that in healthy middle aged people the small risk of bleeding on aspirin partly offsets the benefit from prevention of strokes and heart attacks, but the reductions in deaths due to several common cancers will now alter this balance for many people.Peter RothwellLancet.Published Online December 7, 2010 Peter Rothwell

100mg

100mg/d20102010

2010

+++++++Consider CONSIDER 722465206

72.8%61.8%72.8%61.8%Consider

****ATP IVJNC8obesity2,Trends in vascular and non-vascular mortality rates in UK populationThe figure shows the age standardised annual UK mortality rates for vascular and non-vascular causes ofdeath at ages 35-69 between 1950 and 2005. Throughout this period, vascular mortality rates in middle age in men were about twice those in women, peaking in 1970 and declining linearly by about 2% a year in both sexes (or by almost 70% between 1970 and 2005). The proportion of deaths attributed to vascular disease in middle age also declined between 1970 and 2005, from about 50% to 30% in men and from 40% to 20% in women. The figure also shows age standardised mortality rates from vascular and non-vascular causes for men and women aged 70-79. For both sexes, the absolute mortality rates in old age were about fivefold greater than those in middle age. In old age, vascular mortality rates declined by about two thirds between 1950 and 2005 in both men and women, but non-vascular mortality rates declined to a much lesser extent in this age group. The proportion of deaths attributed to vascular disease in old age declined from about 60% in 1950 to less than 40% in 2005 for both men and women.**68647-55681025737.4%199229.2%RR1.695%CL1.4-2.127.6% vs.14.2%

******

*A2 (TXA2)PDGF-B(TGF-B)PAIchemokine*

ACS /TIA

Reference:1. Drouet L. Cerebrovasc Dis 2002; 13(suppl 1): 16.ADPIIb/IIIaTXA2TXA25

*>140/90****17631899 1101982.

*72353565734%*3TPTBDATUK-TIA1050250-20520

**123()45NFB67 Reduce oxidative stress by eliminating cigarette smoking, reducing dietary fat intake, and administering antioxidant therapeutics Use anti-inflammatory agents to reduce chemokine, cytokine, and growth factor signaling Employ anti-proliferative drugs targeting growth factor receptors to reduce cell proliferation (i.e., post angioplasty restenosis in coronary and carotid atherosclerosis) Reduce excess matrix digestion caused by metalloprotease hyperactivity Reduce NFB signaling with proteasome inhibitors Use antiangiogenesis strategies to delay plaque expansion in therosclerosis and cancer invasion and metastasis Use radiation treatment (not proven to date) to prevent restenosis after angioplasty and stent placement

***consider**